ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 609,15
0,00%
Dow Jones
39 127,80
0,04%
DAX
18 174,60
0,06%
Brent Oil
84,335
-0,16%
Bitcoin
60 698,37
-0,19%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immutep Limited (PBMD)

  7. Immutep Limited (PBMD) Actualités

PBMD

Immutep Limited (PBMD)

Immutep Limited
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PBMD
DateHeureSourceTitreSymboleSociété
23/02/201812h09Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:PBMDImmutep Limited
28/11/201701h12GlobeNewswire Inc.Prima BioMed Becomes ImmutepNASDAQ:PBMDImmutep Limited
22/11/201700h07GlobeNewswire Inc.Prima Secures European Patent Grant for Lead Product IMP321 in CancerNASDAQ:PBMDImmutep Limited
20/11/201707h59GlobeNewswire Inc.Prima BioMed Changes Its Name to Immutep LtdNASDAQ:PBMDImmutep Limited
15/11/201709h11GlobeNewswire Inc.Eftilagimod Alpha (LAG-3Ig Or IMP321) Pre-IND Meeting With the FDANASDAQ:PBMDImmutep Limited
08/11/201723h45GlobeNewswire Inc.New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual...NASDAQ:PBMDImmutep Limited
03/11/201711h01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PBMDImmutep Limited
01/11/201700h15GlobeNewswire Inc.Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017NASDAQ:PBMDImmutep Limited
20/10/201705h23GlobeNewswire Inc.Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017NASDAQ:PBMDImmutep Limited
19/10/201722h41Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:PBMDImmutep Limited
19/10/201722h39Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:PBMDImmutep Limited
17/10/201706h37GlobeNewswire Inc.IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual MeetingNASDAQ:PBMDImmutep Limited
08/09/201707h25GlobeNewswire Inc.Prima Secures Japanese Patent Grant for IMP731 AntibodyNASDAQ:PBMDImmutep Limited
05/09/201709h54GlobeNewswire Inc.Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious DiseaseNASDAQ:PBMDImmutep Limited
30/08/201712h07GlobeNewswire Inc.Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research ProjectNASDAQ:PBMDImmutep Limited
21/08/201702h07GlobeNewswire Inc.Prima BioMed Appoints Non-Executive Director to the BoardNASDAQ:PBMDImmutep Limited
16/08/201704h01GlobeNewswire Inc.Prima BioMed Receives A $1.3 Million Tax Refund From French GovernmentNASDAQ:PBMDImmutep Limited
18/07/201702h33GlobeNewswire Inc.Financial Update 2H17NASDAQ:PBMDImmutep Limited
17/07/201702h37GlobeNewswire Inc.Prima BioMed Announces Second Milestone Payment for IMP701 ProgramNASDAQ:PBMDImmutep Limited
14/07/201719h45Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:PBMDImmutep Limited
10/07/201705h46GlobeNewswire Inc.Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical TrialNASDAQ:PBMDImmutep Limited
30/06/201723h21Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PBMDImmutep Limited
29/06/201717h39GlobeNewswire Inc.Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary SharesNASDAQ:PBMDImmutep Limited
28/06/201723h22Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:PBMDImmutep Limited
26/06/201712h33GlobeNewswire Inc.Operational UpdateNASDAQ:PBMDImmutep Limited
05/06/201702h36GlobeNewswire Inc.LAG-3Ig (IMP321) Demonstrates Positive Safety and Efficacy Qualities in Breast Cancer Clinical TrialNASDAQ:PBMDImmutep Limited
01/06/201702h54GlobeNewswire Inc.Prima BioMed Announces Formation of Clinical Advisory BoardNASDAQ:PBMDImmutep Limited
18/05/201702h27GlobeNewswire Inc.Data From Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO ConferenceNASDAQ:PBMDImmutep Limited
19/04/201703h45GlobeNewswire Inc.Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma TrialNASDAQ:PBMDImmutep Limited
12/04/201710h25GlobeNewswire Inc.Prima BioMed Receives A$492,144 Tax Refund From Australian GovernmentNASDAQ:PBMDImmutep Limited
 Showing the most relevant articles for your search:NASDAQ:PBMD

Dernières Valeurs Consultées

TG
A3K322
CEZ
NYSE
MTVC
Motive Capital Corp II
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés